Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors

(2012) L. Schirosi et al.   ANNALS OF ONCOLOGY

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors

(2012) C. Miranda et al.   CLINICAL CANCER RESEARCH

Sunitinib Therapy for Melanoma Patients withKITMutations

(2012) David R. Minor et al.   CLINICAL CANCER RESEARCH

Therapeutic targeting of c-KIT in cancer

(2012) Leonie K Ashman et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma

(2012) J R Todd et al.   ONCOGENE

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor

(2011) Akira Sawaki et al.   CANCER

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration

(2011) Jin Hyun Cho et al.   INVESTIGATIONAL NEW DRUGS

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance

(2011) Lu Si et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1

(2011) Kathy Gately et al.   JOURNAL OF CLINICAL PATHOLOGY

The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma

(2011) Ruixia Liang et al.   Pigment Cell & Melanoma Research

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

(2010) D Handolias et al.   BRITISH JOURNAL OF CANCER

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor

(2010) Wei-Lien Wang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor

(2010) Mrinal M. Gounder et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model

(2010) C. Cullinane et al.   MOLECULAR CANCER THERAPEUTICS

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Gastrointestinal stromal tumors

(2010) Bernadette Liegl-Atzwanger et al.   VIRCHOWS ARCHIV

Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors

(2009) Sebastian Haferkamp et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

KIT as a Therapeutic Target in Melanoma

(2009) Maria C. Garrido et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Activate and resist: L576P-KIT in GIST

(2009) E. Conca et al.   MOLECULAR CANCER THERAPEUTICS

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2009) S. E. Woodman et al.   MOLECULAR CANCER THERAPEUTICS

Molecular Pathobiology of Gastrointestinal Stromal Sarcomas

(2008) Christopher L. Corless et al.   Annual Review of Pathology-Mechanisms of Disease

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

(2008) I Satzger et al.   BRITISH JOURNAL OF CANCER

MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth

(2008) Yuichi Takayama et al.   CANCER LETTERS

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

(2008) B Liegl et al.   JOURNAL OF PATHOLOGY

Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors

(2008) W-b Ou et al.   ONCOGENE